The utility of PAX5 immunohistochemistry in the diagnosis of undifferentiated malignant neoplasms

Modern Pathology

Volumn 20, Issue 8, 2007, Pages 871-877

  Jensen, Kristin C ^a,b   Higgins, John P T ^a   Montgomery, Kelli ^a   Kaygusuz, Gulsah ^c   Van De Rijn, Matt ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

B cell; Hodgkin lymphoma; Non Hodgkin lymphoma; PAX5; Undifferentiated neoplasm

Indexed keywords

CD20 ANTIGEN; CD45RB ANTIGEN; CELL MARKER; TRANSCRIPTION FACTOR PAX5;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYME CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UNDIFFERENTIATED CARCINOMA;

ANTIGENS, CD20; ANTIGENS, CD45; B-CELL-SPECIFIC ACTIVATOR PROTEIN; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINEAGE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, NON-HODGKIN; MESODERM; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; TISSUE ARRAY ANALYSIS;

EID: 34447556792     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800831     Document Type: Article

References (34)

1. Palmisano WA, Crume KP, Grimes MJ, et al. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers. Cancer Res 2003;63:4620-4625.
2. Schafer BW. Emerging roles for PAX transcription factors in cancer biology. Gen Physiol Biophys 1998;17:211-224.
3. Adams B, Dorfler P, Aguzzi A, et al. Pax-5 encodes the transcription factor BSAP and is expressed in B lymphocytes, the developing CNS, and adult testis. Genes Dev 1992;6:1589-1607.
4. Hagman J, Wheat W, Fitzsimmons D, et al. Pax-5/BSAP: regulator of specific gene expression and differentiation in B lymphocytes. Curr Top Microbiol Immunol 2000;245:169-194.
5. Barr FG. Chromosomal translocations involving paired box transcription factors in human cancer. Int J Biochem Cell Biol 1997;29:1449-1461.
6. Lin P, Mahdavy M, Zhan F, et al. Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol 2004;17:1217-1222.
7. Torlakovic E, Torlakovic G, Nguyen PL, et al. The value of anti-Pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
8. Zhang X, Lin Z, Kim I. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. J Korean Med Sci 2003;18:804-808.
9. Dong HY, Liu Z, Browne P, et al. B-cell malignancies lacking common pan B-cell antigens consistently express PAX-5. Mod Pathol 2004;17(Suppl 1):246A.
10. Adshead JM, Ogden CW, Penny MA, et al. The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. BJU Int 1999;83:1039-1044.
11. Babjuk M, Soukup V, Mares J, et al. The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome. Int Urol Nephrol 2002;34:495-501.
12. Baumann Kubetzko FB, Di Paolo C, Maag C, et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004;25:1839-1846.
13. Gerard M, Abitbol M, Delezoide AL, et al. PAX-genes expression during human embryonic development, a preliminary report. C R Acad Sci III 1995;318:57-66.
14. Kozmik Z, Sure U, Ruedi D, et al. Deregulated expression of PAX5 in medulloblastoma. Proc Natl Acad Sci USA 1995;92:5709-5713.
15. Urbanek P, Fetka I, Meisler MH, et al. Cooperation of Pax2 and Pax5 in midbrain and cerebellum development. Proc Natl Acad Sci USA 1997;94:5703-5708.
16. Jaffe ES, Harris NL, Stein H, et al. (eds). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyon, 2001, pp 351.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847.
18. Natkunam Y, Mason DY. Prognostic immunohistologic markers in human tumors: why are so few used in clinical practice? Lab Invest 2006;86:742-747.
19. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
20. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007.
21. Shaffer AL, Wright G, Yang L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 2006;210:67-85.
22. Morrison AM, Nutt SL, Thevenin C, et al. Loss- and gain-of-function mutations reveal an important role of BSAP (Pax-5) at the start and end of B cell differentiation. Semin Immunol 1998;10:133-142.
23. Rolink AG, Schaniel C, Andersson J, et al. Selection events operating at various stages in B cell development. Curr Opin Immunol 2001;13:202-207.
24. Nutt SL, Heavey B, Rolink AG, et al. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 1999;401:556-562.
25. Browne P, Petrosyan K, Hernandez A, et al. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-777.
26. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998;92:1308-1316.
27. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, et al. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002;21:4908-4920.
28. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505-1512.
29. Nutt SL, Morrison AM, Dorfler P, et al. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998;17:2319-2333.
30. Uehira K, Amakawa R, Ito T, et al. A Hodgkin's disease cell line, KM-H2, shows biphenotypic features of dendritic cells and B cells. Int J Hematol 2001;73:236-244.
31. Balzer BL, Harvell JD, Natkunam Y. Cutaneous Hodgkin lymphoma: an analysis of six cases. Mod Pathol 2004;17:89A.
32. Stuart ET, Kioussi C, Aguzzi A, et al. PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1995;1:207-214.
33. Dong HY, Liu W, Cohen P, et al. B-cell specific activation protein encoded by the PAX-5 gene is commonly expressed in Merkel cell carcinoma and small cell carcinomas. Am J Surg Pathol 2005;29:687-692.
34. Torlakovic E, Slipicevic A, Robinson C, et al. Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol 2006;126:798-804.